Curasight A/S CURAS

Updated: 11 Jun 2026

Spotlight | Biotech | Biotechnology and cancer therapy

No signal published yet

We already track Curasight and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Curasight free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
Spotlight
Type
Biotech
Sector
Biotechnology and cancer therapy
We're already tracking Curasight A/S — here are the latest events we've registered

Recent News

  • On June 8, 2026, the company announced positive preliminary results from its Phase 1 clinical trial of uTREAT in patients with glioblastoma (brain cancer). The data demonstrated a favorable safety profile and high tumor uptake, providing clinical validation for the company's targeted radiopharmaceutical approach.

What Firelda Watch includes for Curasight A/S

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Curasight A/S will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Hansa Biopharma AB (publ)
HNSA
HOLD
Bioarctic
BIOA B
BUY
Sprint Bioscience AB (publ)
SPRINT
NEUTRAL
Xbrane Biopharma AB (publ)
XBRANE
HOLD
SynAct Pharma AB
SYNACT
HOLD

Biotech

More companies in this sector

Want to follow Curasight A/S? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Curasight free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Curasight A/S CURAS
Curasight — follow and we'll monitor it
Follow Curasight free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.